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REVIEW
Why are somatic diseases in bipolar disorder 
insufficiently treated?
René Ernst Nielsen1,2* , Pirathiv Kugathasan1,2, Sune Straszek1,2, Svend Eggert Jensen1,3 and Rasmus W. Licht1,2
Abstract 
Background: Somatic diseases, including cardiovascular, respiratory, and cancer diseases, are the main contributors 
to a shortened life expectancy of 10–20 years in patients with bipolar disorder as compared to the general popula-
tion. In the general population an increase in survival has been observed over the last decades, primarily due to 
the advances in primary prophylaxis, medical treatment and progress in early detection and monitoring of somatic 
diseases. In this narrative review, we discuss the existing literature on treatment and outcomes of cardiovascular, 
respiratory, and cancer diseases in patients with bipolar disorder, and put this in the context of findings in studies on 
patients diagnosed with other severe mental disorders.
Main body: The existing literature suggests that patients with bipolar disorder receive fewer or delayed medical 
interventions, when admitted with severe somatic diseases, compared to those not diagnosed with bipolar disorder. 
Cardiovascular disease is the most investigated disease regarding outcomes in patients with severe mental illness, and 
novel findings indicate that the increased mortality following cardiac events in these patients can be reduced if they 
are intensively treated with secondary prophylactic cardiac intervention. Elderly patients diagnosed with mental dis-
orders and cancer experience a delay in receiving specific cancer treatment. No studies have investigated treatment 
outcomes in patients with severe mental disease and respiratory diseases.
Conclusion: It is surprising and of major concern that patients with bipolar disorder have not benefitted from the 
significant improvement that has taken place over time over time of somatic treatments in general, especially in 
countries with equal and free access to healthcare services. Therefore, no matter whether this situation is a result of a 
negative attitude from health care providers to patients with mental illness, the result of the patient’s lack of aware-
ness of their physical illness or the results of other factors, further attention including research on developing strate-
gies for improving the management of somatic diseases in patients with bipolar disorder is needed.
Keywords: Bipolar disorder, Mortality, Morbidity, Somatic illness
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Background
Data from both primary and secondary care have shown 
that bipolar disorder is associated with an increased 
relative mortality rate over time as compared to the gen-
eral population (Hoang et  al. 2011; Hayes et  al. 2015, 
2017; John et al. 2018; Staudt Hansen et al. 2018); some 
data even suggest that an increased life expectancy in 
the general population is the primary driver, more than 
a decreased life expectancy in patients with bipolar 
disorder (Hayes et al. 2017). A recent meta-analysis indi-
cated that for patients diagnosed with bipolar disorder, 
the standardized mortality ratio (SMR) due to suicide 
was 13–16 times higher, compared to the SMR of 1.7 
for natural causes of death as compared to the general 
population (Hayes et al. 2015). Suicide often occurs early 
in the course of the bipolar disorder (Plans et  al. 2019), 
and therefore results in large percentage contribution 
to the reduced overall life expectancy, despite the rela-
tively low overall number of deaths from this cause (see 
below) (Kessing et  al. 2015; Jayatilleke et  al. 2017). The 
percentage contribution of suicide to the reduced over-
all life expectancy as compared to the general population 
was approximately 13.5%, whereas cardiovascular disease 
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contributed 17.4% and 22.0% to the reduced overall life 
expectancy in males and females, respectively (Jayatilleke 
et al. 2017). As to the contributions to the number of total 
deaths, Westman et al. showed that approximately one in 
three patients with bipolar disorder dies from cardiovas-
cular disease, with almost half dying from other somatic 
diseases (Westman et al. 2013). Likewise, Jayatilleke et al. 
showed that the main causes of death for patients diag-
nosed with severe mental illness (SMI), including bipolar 
disorder, in general were cardiovascular disease (23.9% 
of males and 17.6% of females), cancer (13.5% of males 
and 19.9% of females) and respiratory diseases (16.2% of 
males and 15.4% of females), with 6.7% of males and 4.4% 
of females with SMI having suicide recorded as cause of 
death (Jayatilleke et al. 2017). These findings are similar 
to the findings in older studies which in patients diag-
nosed with bipolar disorder mainly showed an increased 
relative mortality rate caused by cardiovascular and res-
piratory disease with some studies showing an increased 
and others showing no increased risk of cancer as spe-
cific cause of death (Roshanaei-Moghaddam and Katon 
2009) with the main causes of death being cardiovascular 
disease, cancer and infection in the general population 
(Nielsen et al. 2013).
In the present review, we describe the findings regard-
ing treatment and mortality of patients diagnosed with 
bipolar disorder treated for either cardiovascular dis-
ease, respiratory disease or cancer, as well as discuss the 
findings in relation to studies on non-bipolar patients 
diagnosed with SMI when relevant, as these somatic 
comorbidities are the main causes of death in patients 
with bipolar disorder as outlined above. A major limita-
tion in all the studies including meta-analyses selected for 
review is the lack of reporting how the various somatic 
diseases have been diagnosed. However, we assume that 
most cases of somatic disease are diagnosed by clinicians, 
taking patient report, clinical examination and laboratory 
tests into account; at least this is how diagnoses entered 
into administrative registers like the Danish nationwide 
registers, are obtained (Kessing et al. 2015).
Cardiovascular disease
Cardiovascular risk factors like smoking, obesity, hyper-
tension, increased cholesterol or diabetes are twice as 
common in patients diagnosed with bipolar disorder 
as compared to the background population (Birkenaes 
et al. 2007; Hsu et al. 2015), with a possible earlier onset 
of these risk factors in bipolar patients (Birkenaes et  al. 
2007; Goldstein et al. 2009; Chien et al. 2013; Hsu et al. 
2015) resulting in an increased all-cause mortality as 
well as cardiovascular-specific mortality as compared to 
the general population (Laursen et al. 2013; Correll et al. 
2017; Staudt Hansen et al. 2018). The cluster of the risk 
factors hypertension, hyperglycemia, excess abdomi-
nal fat and abnormal cholesterol/triglycerides is termed 
the metabolic syndrome. The rate of mortality as caused 
by cardiovascular disease is approximately doubled in 
patients with bipolar disorder as compared to the back-
ground population, with a decreased life expectancy of 
10 to 15  years (Laursen et  al. 2013). Previous interven-
tion studies in patients with SMI have primarily focused 
on health behavior change, as the most common car-
diovascular risk factors, e.g. smoking, sedentary lifestyle 
and obesity, are modifiable (Kilbourne et  al. 2013; Spe-
yer et  al. 2016; Ashdown-Franks et  al. 2018). Generally, 
these studies have been unable to show an effect of the 
interventions tested when compared to no intervention 
(Kilbourne et  al. 2012, 2013; Speyer et  al. 2016; Ash-
down-Franks et  al. 2018). However, a recent meta-anal-
ysis showed short term effect of lifestyle interventions in 
patients with SMI on cardiovascular risk factors (Singh 
et al. 2018; Vancampfort et al. 2019). Furthermore, stud-
ies addressing medical conditions and health-risk behav-
ior in patients diagnosed with schizophrenia and bipolar 
disorder have shown effect of both metformin and behav-
ioral interventions in reducing obesity, cholesterol, glu-
cose and insulin resistance, as well as effect of bupropion 
and varenicline in reducing tobacco smoking (McGinty 
et al. 2015).
Primary prophylactic treatment, e.g. preventing or 
increasing resistance to a disease that has not occurred, 
in the general population is most often driven by cardio-
vascular risk assessment, e.g. Framingham Heart Score, 
which however might not predict risk of cardiovascular 
events in patients with SMI. Therefore, models specifi-
cally developed to account for the increased cardiovas-
cular risk in patients with SMI should be implemented 
(Osborn et  al. 2015). A newer study on patients diag-
nosed with schizophrenia has shown a dose-dependent 
effect of secondary prophylactic treatment, e.g. prevent-
ing the recurrence of a disease that has already occurred, 
after myocardial infarction (Kugathasan et  al. 2018a, b); 
and moreover that with increasing treatment intensity, 
the patients had a decrease in excess mortality relative 
to the population of patients with myocardial infarction, 
not diagnosed with schizophrenia, until no excess mor-
tality was found with the most intense treatment inves-
tigated. Previously, Laursen et al. showed a lowered rate 
of invasive cardiac procedures in patients diagnosed 
with schizophrenia, schizo-affective disorder or bipolar 
disorder as compared to patients not diagnosed with a 
psychiatric condition (Laursen et  al. 2009). Newer data 
suggests an increased rate of acute myocardial infarction 
in patients with bipolar disorder, with an increased risk 
in patients diagnosed with bipolar disorder as compared 
to patients with schizophrenia, as well as an increased 
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relative mortality rate in patients with bipolar disorder 
as compared to patients with schizophrenia (Bodén et al. 
2015; Wu et al. 2015). Despite the known increased rate 
of mortality in patients with SMI relative to the general 
population as caused by cardiovascular disease, adequate 
treatment of cardiovascular risk factors in these patients 
are often less likely to occur as compared to the patients 
with cardiovascular disease without SMI (Kilbourne 
et al. 2008). Moreover, data suggests medical conditions 
such as hypertension, dyslipidemia, and diabetes being 
more frequently present but not previously diagnosed in 
patients with SMI admitted to hospital as compared to 
controls (Briskman et  al. 2012). The lack of prophylac-
tic treatment, or factors related to the bipolar disorder 
itself results in an increased rate of pulmonary embo-
lism (Strudsholm et  al. 2005) and an increased rate of 
stroke (Wu et  al. 2013; Prieto et  al. 2014), as compared 
to the general population. Furthermore, data on intra-
venous thrombolysis in the treatment of stroke shows 
that patients with SMI are frequently less treated than 
patients not diagnosed with a psychiatric disorder (Bon-
giorno et al. 2018).
A shared link in pathophysiology between bipolar 
disorder and diabetes has been proposed (Calkin et  al. 
2013), with common genetic links, epigenetic factors as 
well as lifestyle and treatment of bipolar disorder being 
factors associated with a poorer glycemic control and a 
worse general outcome of diabetes and cardiovascular 
disease as a whole (Calkin et  al. 2013). Furthermore, a 
reduced cerebrovascular reactivity among adolescents 
with bipolar disorder compared to psychiatrically healthy 
controls has been observed, suggesting a poorer cerebro-
vascular health (Urback et al. 2018).
Respiratory disease
Data on respiratory disease in patients with SMI is 
scarcer as compared to data on cardiovascular morbidity 
and mortality, but respiratory symptoms are frequently 
described by patients (Burke et al. 2018). A doubled prev-
alence of approximately 6% as well as an almost doubled 
incidence of diagnosed chronic obstructive pulmonary 
disease (COPD) have been described in patients with 
bipolar disorder as compared to the general population 
(Hsu et  al. 2017). Similar to the data on cardiovascular 
disease, the link between COPD and bipolar disorder is 
bidirectional with a 40% increased incidence of bipolar 
disorder in patients with COPD as compared to those 
not diagnosed (Tsai et al. 2016; Su et al. 2017). Similar to 
COPD, a link between asthma and bipolar disorder has 
been shown, with an increased incidence of bipolar disor-
der in patients with asthma, and with prednisolone treat-
ment further increasing the risk of a bipolar diagnosis 
(Lin et al. 2014), as well as asthma being more common 
in patients diagnosed with bipolar disorder than in con-
trols (Patten and Williams 2007; Perugi et al. 2015).
Despite these findings, the treatment effects on COPD 
or asthma in patients diagnosed with bipolar disorder or 
any other SMI diagnosis have not yet been investigated.
Cancer
Studies have shown both an increased and no increased 
incidence of cancer in patients diagnosed with bipo-
lar disorder as compared to the general population 
(McGinty et al. 2012; Martinsson et al. 2016). Some data 
suggests an increased incidence of cancers in the diges-
tive tract, in the respiratory system and in the endocrine 
glands in patients with bipolar disorder (Martinsson et al. 
2016), whereas other data shows an increased risk only 
in males with bipolar disorder (Lin et al. 2013). The dif-
ferences in incidence could be a result of differences in 
study populations as well as differences in the follow-up 
time in studies. Cancer most often is diagnosed after the 
age of 60 years, which could bias data due to the generally 
increased mortality rate in patients with bipolar disorder 
resulting in patients possibly dying due to other causes 
before a cancer could be diagnosed (Howard et al. 2010; 
Guan et al. 2013).
Compared to the general population, patients with 
SMI have an increased mortality after cancer diagno-
sis, independent of cancer stage (Manderbacka et  al. 
2017; Toender et  al. 2018). Strikingly, no increased risk 
of advanced cancers at diagnosis has been observed in 
patients diagnosed with SMI as compared to the gen-
eral population (Chang et  al. 2014), suggesting that dif-
ferences in survival may be due to treatment and course 
after cancer diagnosis and not due to a delayed diagnosis. 
Studies investigating the treatment of cancers in patients 
with mental illness have in fact shown a reduced chance 
of surgery for patients with oral cancer with or without 
adjuvant therapy, and patients with mental illness had an 
increased mortality rate as compared to controls (Chang 
et  al. 2013). Similar findings were seen in patients with 
a diagnosed mood disorder and breast cancer in which 
patients with a mood disorder had an overall poorer out-
come, albeit patients diagnosed with bipolar disorder did 
not have an increased mortality rate (Kanani et al. 2016). 
Elderly patients diagnosed with mental disorders showed 
a delay in initiation of cancer treatment, perhaps explain-
ing some of the differences in mortality between patients 
with mental illness and the general population (Iglay 
et al. 2017a), and highlighting the possible need for coor-
dinated treatment to ensure similar treatment outcomes 
and options in patients with SMI as compared to patients 
without a psychiatric disorder (Cole and Padmanabhan 
2012; Iglay et al. 2017b).
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Discussion
Patients with bipolar disorder have an increased mor-
tality rate relative to the general population, and the 
main causes of death are somatic diseases (Hayes et al. 
2017; John et al. 2018; Staudt Hansen et al. 2018). The 
underlying factors resulting in an increased mortal-
ity rate in patients with bipolar disorder and SMI in 
general are not fully elucidated, but concerns regard-
ing disparity in diagnosis of risk factors, primary pro-
phylactic intervention, secondary prophylactic efforts 
and treatment have been raised (Mitchell et  al. 2014) 
although direct links to psychiatric related factors like 
genetic load, treatment or non-acceptance of offered 
treatment, cannot be ruled out.
Patients with bipolar disorder may not be offered 
diagnostic procedures or treatment for somatic dis-
eases simply because of the psychiatric diagnosis per 
se or because they are unable to follow current treat-
ment regiments due to the disorder. In general, there is 
data supporting a less positive attitude towards patients 
with SMI resulting in poor communication, disregard 
for patients’ dignity and delays in investigation or treat-
ment in the physical treatment setting (Happell et  al. 
2012; Neupane et al. 2016; Noblett et al. 2017), as well 
as in the community (Mirnezami et  al. 2016). Several 
experts have proposed the initiation of coordinated 
or combined treatment options with collaboration 
between specialized psychiatric and somatic care for 
patients with SMI to increase the likelihood of optimal 
treatment as well as reducing attrition rates of patients 
treated (Fleischhacker et  al. 2008; Nielsen and Licht 
2018). The increased collaborative treatment options 
proposed have also been endorsed by associations and 
societies associated with mental health, diabetes and 
cardiology (De Hert et al. 2009).
In general, there is a lack of investment in primary 
treatment of bipolar disorder as compared to other severe 
mental disorders, and especially as compared to somatic 
diseases (MacEwan et al. 2016). This might also be driv-
ing the increased mortality rate in patients with bipolar 
disorder, as well as other patients diagnosed with SMI, 
since patients with insufficiently treated SMI may be less 
likely to seek help for somatic illness and less likely to 
adhere to relevant treatments for these illnesses. On the 
other hand, the current available psychopharmacologi-
cal treatments for SMI have been shown to increase the 
rate and severity of multiple somatic disorders includ-
ing cardiovascular and respiratory diseases (Correll et al. 
2015; Wu et al. 2018), but they seem to reduce the risk of 
intentional self-harm as cause of death (Khan et al. 2013). 
Generally, there is a lack of data on effects for somatic ill-
nesses in patients with SMI, and the field seems generally 
poorly prioritized in terms of research.
In patients with bipolar disorder admitted due to 
somatic illness, a more severe course of the somatic dis-
ease has been observed, and more co-morbidities diag-
nosed, as compared to age- and gender-matched controls 
also admitted (Schoepf and Heun 2014). These findings 
could be interpreted as patients with bipolar disorder 
being susceptible to more severe somatic disease, which 
might not be modifiable, but could also be a result of a 
lack of primary and secondary prophylaxis, as well as a 
lack of sufficient treatment of diagnosed somatic mor-
bidities. Previous data in patients with SMI have shown 
a need for intensified treatment to remove the differ-
ences in mortality rates after myocardial infarction, 
showing increasing mortality rates with decreasing treat-
ment intensity when compared to the general popula-
tion (Kugathasan et  al. 2018a, b). Furthermore, data 
supports a lowered use of treatment for cardiovascular 
disease including thrombolytics for stroke (Bongiorno 
et al. 2018) and lower rates of cardiovascular prophylactic 
treatment (Laursen et al. 2009, 2014). Lastly, data on can-
cer show a similar stage when diagnosed, but a reduced 
likelihood of receiving surgery and adjuvant treatment, 
and shows a poorer survival as compared to patients not 
diagnosed with SMI (Chang et  al. 2013, 2014; Mander-
backa et al. 2017; Toender et al. 2018).
Treatment for somatic disease has significantly 
improved over the last decades with implementation of 
improved diagnostics, better primary and secondary pro-
phylactic treatment options, as well as a general reduc-
tion in lifestyle behavior associated with somatic disease 
(Roth et al. 2015; Korhonen et al. 2017). During the same 
time period, an increasing excess mortality relative to 
the general population has been seen in patients with 
bipolar disorder (Hayes et al. 2017; Staudt Hansen et al. 
2018), perhaps suggesting a lack of benefit in the popula-
tion of patients with SMI of the general improvements in 
somatic treatments (Armstrong et al. 1999; Laursen and 
Nordentoft 2011; Lautrup et  al. 2018; Kugathasan et  al. 
2018a, b; Degett et al. 2019).
Conclusion
Patients with bipolar disorder have an excess mortal-
ity with somatic diseases most often being defined as 
cause of death. The current management of somatic ill-
ness occurring in patients with bipolar disorder has not 
been able to decrease the mortality gap between the gen-
eral populations and patients with bipolar disorder, and 
the underlying factors could be both patient as well as 
treatment setting related. Data has shown an increased 
survival in the general population, most likely due to 
improvements in treatments as well as prophylaxis, but 
these interventions are used less often in patients with 
bipolar disorder and SMI in general, perhaps, at least in 
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part, as a result of negative attitudes towards patients 
with SMI. Collaborative care established between psy-
chiatric and somatic treatment facilities might reduce the 
treatment gap, the mortality gap as well as diminish the 
possible negative attitudes towards somatic treatment of 
patients with SMI.
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